Six years ago Abiraterone was hailed as a medical breakthrough that could offer men extra time with loved ones and a chance to delay chemotherapy and its debilitating side effects.
Today the body that recommends what can and cannot be paid for said it 'wasn't cost effective'.
Prostate cancer patients have now been told that the life-extending drug will not be routinely prescribed unless they have chemotherapy.
One man from North Yorkshire who is fighting prostate cancer is calling for a rethink:
More top news
Fine with a cold wind
Slowly becoming milder. Unsettled end to the week.
The National Housing Federation says the average worker in the region would need a 62% pay rise in order to afford a mortgage.